JAN 09, 2021 12:55 PM PST

Potential Bronchodilator for COPD diseases

WRITTEN BY: Nouran Amin

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations or even death.

"Only about 50 percent of asthmatics, and an even lower percentage of people with COPD, achieve adequate control of lung inflammation and airway constriction with currently available medications," said Stephen Liggett, MD, vice dean for research at the University of South Florida Morsani College of Medicine and a USF Health professor of medicine, molecular pharmacology and physiology, and biomedical engineering. "So, we're clearly missing something from our drug armamentarium to help all these patients."

Now, research has found a way to target certain receptors with a promising bronchodilator.

"The two key questions we asked were: 'Is it possible to find a more potent agonist that activates this receptor?' and 'Is it feasible to deliver by inhalation given the potencies that we find?'" said Dr. Liggett, the paper's senior author. "T5-8 was the bronchodilator agonist that worked best. There were a few others that were very good as well, so we now have multiple potential new drugs to carry out the next steps."

Findings were in ACS Pharmacology and Translational Science.

Learn more about COPD diseases:

"The biggest challenge we faced was not having a 3-D crystal structure of TAS2R5, so we had no idea exactly how agonist T5-1 fit into this mysterious bitter taste receptor," Dr. Liggett said. "By merging our strength in receptors, pharmacology, physiology, and drug development, our team was able to make the breakthrough."

"Having two distinct classes of drugs that work in different ways to open the airways would be an important step to help patients optimally control their symptoms."

"This study yielded a drug discovery that successfully meets most of the criteria needed to advance the compound toward its first trial as a potential first-in-class bronchodilator targeting airway receptor TAS2R5."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 21, 2021
Cardiology
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
JUN 21, 2021
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
Research has indicated that there is a connection between gut microbes and heart health. Now scientists are revealing so ...
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUN 24, 2021
Immunology
Gut-Healing Stem Cells to Treat HIV Infections
JUN 24, 2021
Gut-Healing Stem Cells to Treat HIV Infections
A new study has revealed how stem cells can be used to amplify immune responses to HIV, the virus that causes AIDS. The ...
JUL 05, 2021
Microbiology
Natural Antibiotic in Chestnut Leaves Can Eliminate MRSA
JUL 05, 2021
Natural Antibiotic in Chestnut Leaves Can Eliminate MRSA
The natural world is full of microbes, fungi, and plants that have given us valuable medicines, like tetracyclines, peni ...
JUL 08, 2021
Genetics & Genomics
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
JUL 08, 2021
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
Children with Down syndrome have a significantly higher likelihood myeloid leukemia occurring in the first five years of ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
Loading Comments...